External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

Status Completed

Clinical Trial Summary

Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine clinical care in the OPERA cohort.

Clinical Trial Description

The US Department of Health and Human Services (DHHS) HIV treatment guideline suggest that ibalizumab may be considered in the context of multidrug resistance without fully active ART options. However, clinical trials assessing ibalizumab efficacy did not include an active comparison arm in which participants did not receive ibalizumab. The use of external controls can provide valuable information and context to interpret the results of clinical trials when randomization to a control arm cannot be performed. The OPERA (Observational Pharmaco-Epidemiology Research & Analysis) cohort, a large US electronic health record database, is well suited for this as the OPERA and trials populations arose from the same geographic location (i.e., US). An external comparison of ibalizumab + optimized background regimen from trials vs. non-ibalizumab containing regimens in routine clinical care in the OPERA cohort may confirm results from prior studies suggesting viral control benefits of ibalizumab. ;

Study Design

Related Conditions & MeSH terms

HIV-1-infection

Clinical Trial Details

NCT number	NCT05495204
Study type	Observational
Source	Epividian
Contact
Status	Completed
Phase
Start date	August 5, 2022
Completion date	February 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03940521` - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Completed	`NCT03227731` - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women	Phase 2/Phase 3
Completed	`NCT03570918` - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy	Phase 1
Not yet recruiting	`NCT06336434` - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy	Phase 1/Phase 2
Active, not recruiting	`NCT04022967` - ANRS 12372 MODERATO Study	Phase 3
Not yet recruiting	`NCT06337032` - A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments	Phase 4
Not yet recruiting	`NCT06282783` - Studying Topiramate for Re-Activating the HIV-1 Reservoir	Phase 1/Phase 2
Completed	`NCT04711265` - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting	`NCT03536234` - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients	Phase 2
Completed	`NCT04340388` - Contribution of Dolutegravir to Obesity and Cardiovascular Disease	Phase 4
Withdrawn	`NCT05769569` - Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission	Phase 1
Enrolling by invitation	`NCT05584397` - Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
Not yet recruiting	`NCT04894357` - Impact of V106I on Resistance to Doravirine
Completed	`NCT04963712` - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder	Early Phase 1
Completed	`NCT04388904` - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)	Phase 4
Not yet recruiting	`NCT04513496` - Telemedicine in HIV Care in Buenos Aires
Not yet recruiting	`NCT04311944` - Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD	N/A
Completed	`NCT04568239` - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Not yet recruiting	`NCT04311957` - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults	Phase 4
Completed	`NCT03998176` - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE	Phase 4